Tizoxanide

Tizoxanide
Names
	IUPAC name 2-Hydroxy-N-(5-nitro-2-thiazolyl)benzamide
	Other names Desacetyl-nitazoxanide
Identifiers
CAS Number	173903-47-4 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL1545 ;
ChemSpider	349588 ;
ECHA InfoCard	100.263.225
PubChem CID	394397;
UNII	15KFG88UOJ ;
CompTox Dashboard (EPA)	DTXSID40169680 ;
	InChI InChI=1S/C10H7N3O4S/c14-7-4-2-1-3-6(7)9(15)12-10-11-5-8(18-10)13(16)17/h1-5,14H,(H,11,12,15) Key: FDTZUTSGGSRHQF-UHFFFAOYSA-N ; InChI=1/C10H7N3O4S/c14-7-4-2-1-3-6(7)9(15)12-10-11-5-8(18-10)13(16)17/h1-5,14H,(H,11,12,15) Key: FDTZUTSGGSRHQF-UHFFFAOYAR;
	SMILES O=C(Nc1ncc(s1)[N+]([O-])=O)c2ccccc2O;
Properties
Chemical formula	C10H7N3O4S
Molar mass	265.25 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Tizoxanide, also known as desacetyl-nitazoxanide, is a thiazolide and an antiparasitic agent that occurs as a metabolite of nitazoxanide in humans through hydrolysis.[1] Tizoxanide may undergo further metabolism via conjugation into tizoxanide glucuronide.[2][3]

References

Korba BE, Montero AB, Farrar K, et al. (January 2008). "Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication". Antiviral Res. 77 (1): 56–63. doi:10.1016/j.antiviral.2007.08.005. PMID 17888524.
"Nitazoxanide Prescribing Information" (PDF). Romark Pharmaceuticals. August 2013. pp. 1–5. Retrieved 3 January 2016.
Stockis A, Allemon AM, De Bruyn S, Gengler C (May 2002). "Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses". Int J Clin Pharmacol Ther. 40 (5): 213–220. doi:10.5414/cpp40213. PMID 12051573.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid17888524-1] Korba BE, Montero AB, Farrar K, et al. (January 2008). "Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication". Antiviral Res. 77 (1): 56–63. doi:10.1016/j.antiviral.2007.08.005. PMID 17888524.

[FDA_Nitazoxanide-2] "Nitazoxanide Prescribing Information" (PDF). Romark Pharmaceuticals. August 2013. pp. 1–5. Retrieved 3 January 2016.

[Primary:_Kinetics_and_OD-3] Stockis A, Allemon AM, De Bruyn S, Gengler C (May 2002). "Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses". Int J Clin Pharmacol Ther. 40 (5): 213–220. doi:10.5414/cpp40213. PMID 12051573.